Endocrine Abstracts

The purpose of the study: is to assess the quality of life of patients with type 2 diabetes before treatment with hemodialysis using the WHO Brief Questionnaire for the Assessment of Quality of Life (WHOQOL-BREF) and the Hamilton Depression Scale, taking into account the degree of neuromarker S100.

Material and methods: We examined in total for the period from January 1, 2018 to January 1, 2021 - 90 patients suffering from type 2 diabetes mellitus with chronic renal failure (CRF) on programmed hemodialysis.

Results: We analyzed 90 cases of grade 5 diabetic nephropathy who were on programmed hemodialysis. Of these, women -43, men -47. The obtained results also confirm the literature data that patients with type 2 diabetes mellitus have low quality of life indicators before programmed hemodialysis. According to the degree of chronic brain ischemia (CBl), patients were divided into 3 groups: 1 gr. - 36 (40.0%) patients with diabetic nephropathy (DN) 5 stage with CBI 1 degree; 2 gr. - 32 (35.5%) patients with DN 5 stage with CBI 2 degree; 3 gr. - 22 (24.4%) patients with DN 5 stage with CBI 3 degrees. A reliable difference between the mean values of S100 in the blood in patients 2 and 3 groups compared with the rate indicators was detected. In addition, in 2 and 3 groups of patients revealed direct correlation with the quality of life in 3 questionnaires - WHOQOL-BREF), MMSE test and Hamilton depression scales.

Conclusions: Assessing the quality of life using the WHOQOL-BREF scale, determining the level of anxiety and depression, as well as the MMSE test must act as the criteria for the clinical and functional severity of the state and the effectiveness of the treatment of therapy in patients with CRF in the conditions of therapy with various methods.